Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol Oral Solution in Social Anxiety Disorder
NCT05600114Phase 2
Key facts
- Status
- Completed
- Start
- Oct 2022
- Primary completion
- Dec 2023
- Countries
- 1
- Sponsor
- EmpowerPharm Inc.
- Modality
- Small Molecules
- Drugs
- cannabidiol
- Conditions
- Social Anxiety Disorder (SAD)
01
Overview
Phase 2, randomised, double-blind trial of cannabidiol in Social Anxiety Disorder (SAD) (3 arms), sponsored by EmpowerPharm Inc. Primary endpoint: Liebowitz Social Anxiety Scale at 10 weeks. Started Oct 2022; status: completed.
02
Design
3 arms- Study design
- RandomizedDouble-blind
CBD 300 mg/day
Cannabidiol 150 mg BID
CBD 600 mg/day
Cannabidiol 300 mg BID
Placebo
Matching Placebo BID
03
Who it enrols
Adults with a clinically predominant diagnosis of Social Anxiety Disorder (SAD) and an LSAS score >= 70. Excludes patients with other primary psychiatric disorders, recent substance abuse, significant suicide risk, or current cannabis use.
04
Endpoints
Primary
Liebowitz Social Anxiety Scale
Secondary
Clinical Global Impression of Improvement
05
Results
Primary endpoints met
Beyond the preview
Go deeper on NCT05600114.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05600114.